Immunosuppressive therapy and post-transplant malignancy

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1097-1103

  Domhan, Sophie ^a,b   Zeier, Martin ^b   Abdollahi, Amir ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; Immunosuppressive drugs; Transplantation

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DASATINIB; DEFOROLIMUS; EFALIZUMAB; EVEROLIMUS; FINGOLIMOD; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; SOTRASTAURIN; TACROLIMUS; TEMSIROLIMUS;

ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; GRAFT RECIPIENT; GRAFT REJECTION; HEPATOBILIARY SYSTEM CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MESENCHYMOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SKIN CARCINOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSPLANTATION; TREATMENT RESPONSE;

AZATHIOPRINE; CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; NEOPLASMS; ORGAN TRANSPLANTATION; PROPYLENE GLYCOLS; PROTEIN KINASES; SPHINGOSINE;

EID: 65349143361     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn605     Document Type: Editorial

References (83)

1. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628
2. Wimmer CD, Rentsch M, Crispin A et al. The janus face of immunosuppression-de novo malignancy after renal transplantation: the experience of the TransplantationCenter Munich. Kidney Int 2007; 71: 1271-1278
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998; 147-158
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691
5. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000; 23: 101-113
6. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348
7. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501
8. Yokogami K,Wakisaka S, Avruch J et al. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000; 10: 47-50
9. Klampfer L. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 2006; 6: 107-121
10. Majewski M, Korecka M, Kossev P et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virustransformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97: 4285-4290
11. Garcia VD, Bonamigo Filho JL, Neumann J et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003; 16: 202-206
12. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762
13. Lebbe C, Euvrard S, Barrou B et al. Sirolimus conversion for patients with posttransplantKaposi's sarcoma. Am J Transplant 2006; 6: 2164- 2168
14. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317- 1323
15. Sodhi A, Chaisuparat R, Hu J et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcomaassociated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10: 133-143
16. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128- 135
17. Haritunians T, Mori A, O'Kelly J et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007; 21: 333-339
18. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
19. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008; 372: 449-456
20. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671- 688
21. Kauffman HM, Cherikh WS, Cheng Y et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889
22. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-449
23. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589
24. Kahan BD, Yakupoglu YK, Schoenberg L et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80: 749-758
25. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
26. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. Report on Carcinogens, Eleventh Edition. Available at http://ntp.niehs.nih.gov/ntp/roc/toc11.html
27. O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874
28. Swann PF,Waters TR, MoultonDC et al. Role of postreplicativeDNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-1111
29. McGeown MG, Douglas JF, Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. Clin Transpl 2000; 193-202
30. Morath C, Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther2003; 41: 465-469
31. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975; 256: 331-333
32. Carter SB, Franklin TJ, Jones DF et al. Mycophenolic acid: an anticancer compound with unusual properties. Nature 1969; 223: 848-850
33. Brewin TB, Cole MP, Jones CT et al. Mycophenolic acid (NSC- 129185): preliminary clinical trials. Cancer Chemother Rep 1972; 56: 83-87
34. Knudtzon S, Nissen NI. Clinical trial with mycophenolic acid (NSC- 129185), a new antitumor agent. Cancer Chemother Rep 1972; 56: 221-227
35. Messina E, Gazzaniga P, Micheli V et al. Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer 2004; 108: 812-817
36. VegsoG, Sebestyen A, Paku S et al.Antiproliferative and apoptotic effects ofmycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 2007; 31: 1003-1008
37. Takebe N, Cheng X, Fandy TE et al. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 2006; 5: 457-466
38. Koehl GE, Wagner F, Stoeltzing O et al. Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation2007; 83: 607-614
39. Domhan S, Muschal S, Schwager C et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 2008; 7: 1656-1668
40. Chong CR, Qian DZ, Pan F et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006; 49: 2677-2680
41. Wu X, Zhong H, Song J et al. Mycophenolic acid is a potent inhibitor of angiogenesis. Arterioscler Thromb Vasc Biol 2006; 26: 2414- 2416
42. Engl T, Makarevic J, Relja B et al.Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005; 5: 4
43. Collart FR, Huberman E. Expression of IMP dehydrogenase in differentiating HL-60 cells. Blood 1990; 75: 570-576
44. Kiguchi K, Collart FR, Henning-Chubb C et al. Induction of cell differentiation inmelanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity. Cell Growth Differ 1990; 1: 259-270
45. Messina E, Gazzaniga P,Micheli V et al. Low levels of mycophenolic acid induce differentiation of human neuroblastoma cell lines. Int J Cancer 2004; 112: 352-354
46. Takebe N, Cheng X, Wu S et al. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (Cellcept) in advanced multiple myeloma patients. Clin Cancer Res2004; 10: 8301-8308
47. Gu JJ, Santiago L, Mitchell BS. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood 2005; 105: 3270-3277
48. Robson R, Cecka JM, Opelz G et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant2005; 5: 2954-2960
49. O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 1186-1191
50. David KM, Morris JA, Steffen BJ et al.Mycophenolate mofetil versus azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005; 19: 279- 285
51. US Renal TransplantMycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis1999; 34: 296-303
52. Mathew TH. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation 1998; 65: 1450- 1454
53. Halloran P, Mathew T, Tomlanovich S et al. The International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39-47
54. Yopp AC, Ledgerwood LG, Ochando JC et al. Sphingosine 1- phosphate receptor modulators: a new class of immunosuppressants. Clin Transplant 2006; 20: 788-795
55. Tedesco-Silva H, Mourad G, Kahan BD et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79: 1553-1560
56. Shen Y, Cai M, Xia W et al. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett 2007; 254: 288-297
57. Yasui H, Hideshima T, Raje N et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res2005; 65: 7478-7484
58. LaMontagne K, Littlewood-Evans A, Schnell C et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66: 221-231
59. Schmid G, Guba M, Ischenko I et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem 2007; 101: 259-270
60. Sanchez T, Estrada-Hernandez T, Paik JH et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278: 47281-47290
61. Azuma H, Takahara S, Ichimaru N et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 2002; 62: 1410-1419
62. Zhou C, Ling MT, Kin-Wah LT et al. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett 2006; 233: 36-47
63. Neviani P, Santhanam R, Oaks JJ et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408-2421
64. Maluccio M, Sharma V, Lagman M et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597-602
65. Pawelec G,Wernet P. Cyclosporin A inhibits interleukin 2-dependent growth of alloactivated cloned human T-lymphocytes. Int J Immunopharmacol1983; 5: 315-321
66. Masuhara M, Ogasawara H, Katyal SL et al. Cyclosporine stimulates hepatocyte proliferation and accelerates development of hepatocellular carcinomas in rats. Carcinogenesis 1993; 14: 1579-1584
67. Van d V, Marquet RL, Eggermont AM. Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour. J Cancer Res Clin Oncol 1997; 123: 21-24
68. Van Der EJ, De Greve J, Geerts F et al. Quantitative study of liver metastases from colon cancer in rats after treatment with cyclosporine A. J Natl Cancer Inst 1986; 77: 227-232
69. Hojo M, Morimoto T, MaluccioMet al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530- 534
70. Engle SJ, Hoying JB, Boivin GP et al. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999; 59: 3379-3386
71. Siegel PM, Shu W, Cardiff RD et al. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003; 100: 8430-8435
72. Andre N, Roquelaure B, Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses 2004; 63: 647- 652
73. Herman M, Weinstein T, Korzets A et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14-20
74. Vivarelli M, BellusciR,CucchettiAet al. Lowrecurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746-1751
75. Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999; 13: 209-220
76. BustamiRT, OjoAO,WolfeRAet al. Immunosuppression and the risk of post-transplantmalignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93
77. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905- 913
78. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728
79. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs2007; 67: 1167-1198
80. Cherikh WS, Kauffman HM, McBride MA et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289- 1293
81. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222- 230
82. Opelz G, Naujokat C, Daniel V et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227-1233
83. Yabu JM,Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol 2007; 27: 479-486